How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed
US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.
You may also be interested in...
BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.
US congressional ‘coronavirus crisis’ panel explores Emergent BioSolutions COVID-19 vaccine launch failures while scoring points about private sector support.
After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.